Tags : Cepheid

Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital

Tuba Khan May 24, 2019

Shots: The approval follows the clinical study assessing Hologic’s Aptima Combo 2 Assay and Cepheid’s Xpert CT/NG in 2,500+ patients to detect the presence of the bacteria Chlamydia trachomatis and […]readmore

Tags : Cepheid

Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Cepheid

﻿Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital